Sundia MediTech has entered into a strategic alliance for contract research and manufacturing services (CRAMS) in mainland China with ScinoPharm (Changshu) Pharmaceuticals.
Set up in 2004 and based in Shanghai, Sundia MediTech is a leading Chinese clinical research organisation (CRO) offering global drug discovery and development services, with a particular focus on chemistry synthesis and preclinical studies.
ScinoPharm (Changshu) Pharmaceuticals is a subsidiary of ScinoPharm Taiwan, which provides process R&D and active pharmaceutical ingredient (API) manufacturing services to industry worldwide.
It was founded in 2009 and operates out of the Changshu Economic Development Zone in Jiangsu Province.
The two companies will combine resources to establish “a robust collaboration with single-source solutions to address the increasing number of multinational companies shifting their drug-development research and clinical trials in China”, explained Dr Jo Shen, chief executive officer of ScinoPharm Taiwan and chairman of ScinoPharm Changshu.
Sundia’s diversified technical know-how and capabilities in research and development for new medicines will be yoked to ScinoPharm’s expertise in process R&D and commercial production, especially for highly potent oncology APIs.
China is among the first-choice CRAMS destinations in Asia and is likely to witness substantial growth as global R&D expenditure shifts increasingly to outsourcing, the partners noted.
In addition to process R&D and commercial production for generic APIs, ScinoPharm offers an interactive, single-location custom-synthesis service, spanning the entire R&D chain from initial development to product launch.
The company also provides product-registration, regulatory-filing and Good Manufacturing Practice (GMP)-inspection support to both domestic and overseas clients.